Initially, a 6-month course of 3 weekly injections of 3 MUs of IFN-α was approved for treatment of CHC, and a biochemical response, defined as the normalization of ALT levels, was assigned as the primary end point [2, 3]. Here, IFNA2 is linked to cryohydrocytosis.